Trials / Completed
CompletedNCT01544673
Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males
An Open-label, Placebo-controlled Phase 1 Study to Evaluate the Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Results from previous studies have been inconclusive and the effect of linezolid on cytokines remains unclear. This study is designed to evaluate the effect of linezolid on the functionality of white blood cells (neutrophils and monocytes) in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | linezolid | 600 mg oral tablet twice daily for 4.5 days |
| DRUG | Placebo | 500 mg oral placebo twice daily for 4.5 days |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2012-04-01
- Completion
- 2012-04-01
- First posted
- 2012-03-06
- Last updated
- 2012-04-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01544673. Inclusion in this directory is not an endorsement.